Supernus Pharmaceuticals, Inc. has announced that it will host a webcast and conference call on October 17, 2024, at 4:30 p.m. ET to review data from the open-label phase 2a study of SPN-820 for the treatment of major depressive disorder.
The company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. Additionally, they are developing a broad range of novel CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
Investors and stakeholders can access a live webcast with presentation slides via a provided webcast link or in the events & presentations section of the company’s investor relations website. A replay will be available on the company's investor relations website for 60 days following the live call.
This announcement comes as Supernus Pharmaceuticals continues to focus on developing and commercializing products for the treatment of CNS diseases. The webcast and conference call aim to provide insights into the open-label phase 2a study of SPN-820, offering an opportunity for stakeholders to gain valuable information about the company's progress in addressing major depressive disorder. As a result of these announcements, the company's shares have moved -1.5% on the market, and are now trading at a price of $31.89. If you want to know more, read the company's complete 8-K report here.
